(Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists

A method for the treatment of migraine in a mammal comprising administering to a mammal in need of such treatment or prevention an effective amount of a compound of formula I:

• or a pharmaceutically acceptable acid addition salt thereof, where;
• Q is oxygen or sulfur;
• X is —C(R4c)═ or —N═;
• R1 mono- di-, or tri-substituted phenyl wherein the substitutions are independently selected from halo, C1-C2 alkoxy, trifluoromethyl, trifluoromethoxy, and trifluoroethoxy;
• R2 is hydrogen or methyl;
• R3 hydrogen;
• R4a and R4b are hydrogen;
• When X is —C(R4c)═, R4c is hydrogen;
• R5 hydrogen;
• and
• R6 is hydrogen.

A compound of formula I:

• or a pharmaceutically acceptable acid addition salt thereof, where;
• Q is oxygen or sulfur;
• X is —C(H)═ or —N═;
• R1 is a substituted or unsubstituted heterocycle wherein the heterocycle is selected from the group consisting of pyridinyl and thiophenyl;
• R2 is hydrogen or methyl;
• R3 is hydrogen;
• R4a and R4b are hydrogen
• R5 hydrogen;
• and
• R6 is hydrogen.

A method for the treatment of migraine in a mammal comprising administering to a mammal in need of such treatment or prevention an effective amount of a compound of formula I;

• or a pharmaceutically acceptable acid addition salt thereof, where;
• Q is oxygen or sulfur;
• X is —C(H)═ or —N═;
• R1 is a substituted or unsubstituted heterocycle wherein the heterocycle is selected from the group consisting of pyridinyl and thiophenyl;
• R2 is hydrogen or methyl;
• R3 hydrogen;
• R4a and R4b are hydrogen
• R5 hydrogen;
• and
• R6 is hydrogen.